SCHEMBL16385231

SCHEMBL16385231

COc1ccc(-c2cccc(C)n2)cc1Cl

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMO O15229 2/20 0.52
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
CCR1 P32246 1/20 0.46
CCR8 P51685 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
NPC1 O15118 3/20 0.44
RAB9A P51151 3/20 0.44
PTGS2 P35354 3/20 0.44
ADORA2A P29274 1/20 0.44
ADORA1 P30542 1/20 0.44
KDM4E B2RXH2 1/20 0.43
ALDH1A1 P00352 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
TGFBR1 P36897 1/20 0.43
MAPK14 Q16539 1/20 0.43
HSP90AA1 P07900 1/20 0.43
PTGS1 P23219 1/20 0.42
CYP1A1 P04798 1/20 0.41
CYP1A2 P05177 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13680448 0.85 KDM4E (0.58) MEN1KMT2ACCR1CCR8L3MBTL1
SCHEMBL411466 0.85 TGFBR1 (0.43) KMOCCR1CCR8NPC1RAB9A
SCHEMBL16385162 0.84 RAB9A (0.59) MEN1KMT2ACCR1CCR8L3MBTL1
SCHEMBL2615270 0.82 CCR1 (0.54) KMOCCR1CCR8NPC1RAB9A
SCHEMBL16385165 0.81 ALDH1A1 (0.47) MEN1KMT2ACCR1CCR8NPC1
SCHEMBL16385293 0.81 MAPT (0.58) MEN1KMT2ACCR1CCR8NPC1
SCHEMBL15256614 0.81 ALDH1A1 (0.55) MEN1KMT2ACCR1CCR8L3MBTL1
SCHEMBL16421508 0.80 CCR1 (0.52) KMOMEN1KMT2ACCR1CCR8
SCHEMBL28444872 0.79 KMO (0.64) KMOL3MBTL1ADORA2AADORA1KDM4E
SCHEMBL7053613 0.78 HDAC8 (0.47) MEN1KMT2ACCR1CCR8NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3020715-B1 TETRAZOLINONE COMPOUND AND USE THEREOF SUMITOMO CHEMICAL CO (JP) 2021-06-16 EP disclosed
US-9888688-B2 Tetrazolinone compounds and applications thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2018-02-13 US disclosed
US-9888688-B2 Tetrazolinone compounds and applications thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2018-02-13 US disclosed
US-20160150787-A1 TETRAZOLINONE COMPOUNDS AND APPLICATIONS THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2016-06-02 US disclosed
US-20160150787-A1 TETRAZOLINONE COMPOUNDS AND APPLICATIONS THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2016-06-02 US disclosed
WO-2015005499-A1 TETRAZOLINONE COMPOUND AND USE THEREOF 住友化学株式会社 (JP) 2015-01-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160150787-A1 TETRAZOLINONE COMPOUNDS AND APPLICATIONS THEREOF SOD1, UQCRB, MT-CO1 KMO 1701/4885MEN1 3183/4885KMT2A 3139/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.